GlaxoSmithKline subsidiary Adriatic Acquisition Corporation (AAC) has extended the expiration date for its tender offer for US-based Tesaro.
News
Pharma comments on Brexit withdrawal rejection
Pharmaceutical groups weigh in on the UK parliament’s rejection of the Brexit withdrawal agreement.
Psychosis patients waiting for NHS treatment
Over a thousand people with psychosis are still waiting for treatment on the NHS.
‘Professional Standards for Community Pharmacy Services’ to be set
The Royal Pharmaceutical Society has begun to produce its first ever ‘Professional Standards for Community Pharmacy Services’.
Keytruda reduces risk of death compared to chemo
Merck’s Keytruda has been found to reduce risk of death by 31% compared to chemotherapy, when used in previously treated patients with advanced esophageal or esophagogastric junction carcinoma, whose tumours express PD-L1.
‘Ring-fence the prevention budget’ warns top Doctor
Responding to the NHS’ long-term funding plan, experts have cautioned that for progress to be made, the funding must be protected for an appropriate time period.
European Commission approves Opdivo for advanced renal cell carcinoma
The European Commission has approved Bristol-Myers Squibb’s Opdivo in combination with low-dose Yervoy for first-line treatment of patients with intermediate and poor risk advanced renal cell carcinoma (RCC).
SMC OK’s four meds for NHS use, including Roche’s Perjeta
The Scottish Medicines Consortium (SMC) has recommended four medicines – including Roche’s breast cancer drug Perjeta – for use on the NHS.
Approval for Seqirus flu vaccine
Seqirus has announced European approval of its new cell-based quadrivalent influenza vaccine.
Health Canada restricts Allergan’s Esmya
Health Canada has placed restrictions on Allergan’s uterine fibroid treatment Esmya, after discovering a possible link between its use and the risk of a rare but serious liver injury.
UK Government to tackle air pollution
Environment secretary Michael Gove has launched a new ‘world leading plan’ to tackle air pollution.
UK mental health services falling behind those for physical health
A new report on current trends in Schizophrenia services in the UK launched by Janssen has found that mental health services are falling behind physical health services.
PreP Impact trial to double in size
Speed of recruitment and demand for a trial assessing the impact of HIV prevention therapy PrEP has significantly exceeded initial predictions, leading researchers to consider increasing the number of participants from 13,000 to up to 26,000.
Gen Z ‘fearful’ for future of UK health services
A new Pegasus study has found that Generation Z (aged 16-23) has an overwhelming concern that UK health services won’t meet their needs or expectations in the future.
EMA approves Flutiform for children with asthma
The European Medicines Agency (EMA) has approved Flutiform pMDI for use in the treatment of children with asthma aged five years and over.
